PATENT CLAIM ANALYSIS

Application Number: 16065402
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "046000"]

Abstract:
This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer, such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations that comprise a polar aprotic solvent, for example, dimethyl acetamide (DMA).

Claim (Index 10):
The formulation of  claim 1 , wherein the formulation comprises:\n from 30% to 95% by volume DMA; from 5% to 50% by volume aqueous vehicle; and from 100 mg to 400 mg per mL protide.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 94.0
- Lexical Diversity: 1.63265
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15308475', '15308491', '15753237', '15514673', '15411409']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7691987638370124
- 35 USC 102 Novelty (BERT): 0.5352996509562726
- Combined Prediction Score: 0.7458088525489384
- Mean Citation Score: 243.789946
- Max Citation Score: 364.2399
- Similarity Product: 274.178168725419

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test